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INTRODUCTION 
Since 1962, when the first quinolone derivative with 
antibacterial activity, nalidixic acid, was synthesized, 
there has been a concerted and systematic search for 
compounds with enhanced antibacterial activity and/ 
or an improved pharmacokinetic profile. The potent 
activity of nalidixic acid against Gram-negative bacteria 
has been greatly improved and expanded upon by 
combining a 7-piperazinyl ring and a 6-fluorine atom 
on the quinolone nucleus (as in the case of cipro- 
floxacin, norfloxacin and pefloxacin) or on the 1,8- 
naphthyridine nucleus (as in enoxacin), or producing 
fluorinated tricyclic derivatives (levofloxacin and 
ofloxacin). The fluoroquinolones can be divided into 
four groups on the basis of their chemical structure- 
monocyclic, bicyclic, tricyclic and tetracyclic structures 
linked to the pyridone-P-carboxylic acid nucleus-or 
into four biological groups according to their anti- 
bacterial spectrum and extent of metabolic transform- 
ation. The earlier quinolone derivatives have a limited 
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antibacterial spectrum and are active mainly against the 
Enterobacteriaceae. These compounds are character- 
ized by unfavorable pharmacokinetic properties and 
low in vivo potency. The newer derivatives have more 
favorable pharmacokinetic profiles, resulting in higher 
serum concentrations, and have lower minimum 
inhibitory concentrations (MICs), making them appro- 
priate for the treatment of systemic infections [l]. This 
paper focuses on the tissue penetration, intracellular 
accumulation and pharmacodynamics of the fluoro- 
quinolones. 
TISSUE PENETRATION 
It is essential that antibacterial agents used to treat 
infections caused by intracellular bacteria have favorable 
intracellular penetration, accumulation and disposition. 
Concentrations of antibiotics in various tissues have 
attracted considerable interest. The fluoroquinolones 
are able to achieve high concentrations in cells, although 
the exact mechanism by which this occurs is not 
known. Lipophilicity does not seem to play a significant 
role, since some of them are hydrophilic [2 ] .  
As with other antibiotics which exhibit intra- 
cellular accumulation (e.g. tetracyclines, macrolides), 
the concentrations of fluoroquinolones in different 
tissues are often higher than the concurrent serum 
levels. One must, however, bear in mind that tissue 
concentrations are difficult to interpret. Since drugs 
are not distributed evenly throughout the body or 
within a specific tissue, concentrations obtained by 
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homogenizing tissue are inherently inaccurate and, as 
these are mean values of concentrations in different 
tissue compartments, they cannot be used to estimate 
the drug concentration at the site of action [3,4]. This 
is clearly evident from the studies of Baldwin et al, 
where concentrations of ciprofloxacin and lomefloxacin 
in bronchial biopsies, alveolar epithelial lining fluid 
and alveolar macrophages were compared with simul- 
taneous serum levels [5]. The bronchial biopsy concen- 
trations of ciprofloxacin and lomefloxacin were 1.6 
and 1.7 times those of serum, respectively. The 
corresponding values for macrophage concentrations 
were 11.8 and 20.1, respectively. Interestingly, the 
concentrations of the two fluoroquinolones in epithelial 
lining fluid were also higher than in serum (2.1 and 1.9 
times the serum levels, respectively), possibly indicating 
antibiotic delivery to the extracellular site from the 
intracellular antibiotic reservoir. Similar results have 
been obtained with levofloxacin which showed higher 
concentrations in epithelial lining fluid and alveolar 
macrophages than in serum [6] .  
The common bacteria causing acute respiratory 
tract infections are extracellular pathogens. The 
bactericidal action of the antibiotic is thus normally 
required in the interstitial fluid. In most tissues, the 
antibiotic molecules diffuse freely between the vascular 
and interstitial fluid space. Even if serum and interstitial 
fluid levels of antibiotics do not always equilibrate, 
such as in large collections of inflammatory fluid, the 
concentrations of free (non-protein-bound) antibiotic 
are the most useful surrogate markers for the concentra- 
tions achieved at the site of infection for extracellular 
pathogens. However, for respiratory tract infections 
caused by intracellular bacteria, such as Legionella spp. 
and Chlamydia pneumoniae, the high intracellular levels 
of fluoroquinolones may be important. 
lntracellular accumulation of fluoroquinolones 
The cellular pharmacokinetics of antibacterial agents is 
one of the parameters responsible for their intracellular 
activity (Figure 1). Fluoroquinolones are able to con- 
centrate within phagocytic and non-phagocytic cells 
and remain active against different facultative, obligate, 
intracellular pathogens. Many studies have dealt with 
the characteristics of the cellular accumulation of 
fluoroquinolones in vitro, particularly in phagocytic 
cells. 
The classical technique used to determine the 
various parameters of cellular pharntacokinetics (accunl- 
ulation kinetics, cellular location and efflux) involves 
in vitro incubation of the test cells with the drug 
(either radiolabeled or unlabeled) followed by velocity 
centrifugation through a water-impermeable oil cushion 
to separate the free antibiotic (aqueous phase) from the 
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cell-associated drug. Drug measurement may be done 
either by a fluorometric assay, owing to the fluorescent 
property of most fluoroquinolones, or by radioactivity 
counting. The amount of cell-associated drug (ng/x 
cells or ng/mg protein) is determined by standard drug 
dilutions. After determination of the intracellular water 
content (by isotopic techniques, cytometiy, etc.), it is 
possible to calculate the intracellular concentration 
(mg/L) and, from that, the parameter most frequently 
used for comparison, the cellular/extracellular concen- 
tration ratio (C/E).  
It  is important to determine the location of 
the drug (by cell fragmentation techniques), e.g. in 
cytosol, granules or lysosomes, to ensure that the C / E  
ratio represents the true ratio between intra- and 
extracellular concentration. Otherwise, the C / E  ratio 
may just characterize the overall amount of cell- 
associated drug, including the membranes and 
associated ‘true’ intracellular compartments. Drug 
efflux is measured by similar techniques, using drug- 
loaded cells isolated and placed in drug-free medium. 
At repeated time intervals, aliquots are centrifuged and 
the drug measured in both the supernatant and the cell 
pellet to calculate the percentage of drug released. 
Variations in the experimental medium (such as pH and 
inhibitors) and other conditions (such as temperature 
and killed cells) are used to investigate the mechanisms 
underlying drug uptake and efAux. 
The main features of fluoroquinolone cellular 
pharmacokinetics are shown in Table 1 [7-161. The 
Table 1 Comparative cellular pharmacokinetics of fluoroquinolones 
1)rug C / E  ratio Ernux Activity 
(technique) Cell (tinie) (time) (bacteria) Reference 
Ciprofloxacin 
(bioassay) MPH (m) 
(HPLC) PMN 
(fluorometry) PMN 
J774 
Levofloxacin 
(fluorometry) PMN 
Hep 2 
McCoy 
Vero 
Ofloxacin 
(fluoromrtry) 
(HPLC) 
Spadoxacin 
(fluorometry) 
2.7 (30 min) 
4 (30 min to 2 h) to 
8 (5 inin) 
4.7 (20 min) 
8.6 (30 imn) 
4.4 ( 5 min) 
6.1 (20 min) to 
>8.3 (10 min) 
2.1 (10 inin) 
3.9 (10 min) 
2.1 (10 inin) 
ND + (S.a.) 7 
8 
30% (5 min) + (Pa.) 9 
+ (S.a.) 11 
10 
+ (S.a.) 9 
12 
12 
12 
12 
PMN 4.9 (5 min) to 65588% (5 min) + (P.a., Sa.)  9 
7.6 (30 min) 1 0 
Hep 2 2.8 (10 min) 
McCoy 4.7 (10 min) 
Vero 2.4 (10 min) 
WI-38 8.6 (30 min) 
J774 5.3 (5 mill) 
PMN 6.5 (20 min) to 
>13.2 (5 inin) 
Hep 2 7 (20 mm) 
McCoy 10 (20 inin) 
J774 6.4 (30 min) 
+ (S.a.) 
+ (S.e.) 
13 
13 
13 
11 
14 
60% (5 min) + (S.a.) 9 
1 1  
15 
15 
15 
+ (S.3.) 1 1  
Trovafloxaciii 
(I-adioartivity) PMN 11 (20 min) 80% (i min) + (La.) 16 
MPH (h) 10 (20 mill) 65% (5 i n i n )  
McCoy 9.6 (20 niin) 
11, human: 1x1, IIIOUFC: MPH, macrophage: ND, not determined; Pa., Pwudomorras aerrrqqirruru; 
PMN, polymorphonuclear neutrophil; S.a., Stuphylococcus atrmu; S.e., Snlrnoridln enreriridis. 
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upt'ike of most fluoroquinolones is rapid, followed by 
a long-lasting plateau. Whatever the cell species, the 
C / E  ratio is ~ i ~ ~ i a l l y  moderate (i.c. < 10) 1171. The  
cellular location. riiaiiil>- cytosolic, has been determined 
only for fleroxacin, loniefloxacin and pefloxacin [ 181. 
Effl~ix is also rapid, with 60-90%1 of the intracellular 
drug being released within the first 5 min. 
The mechanism underlying the accumulation of 
fluoroquinolones has not been clarified. Fluoroquino- 
lone uptake does n o t  'ippear to he saturable; m o s t  
studies denionstrate that decreasing the incubation 
teniperaturr to 1°C results in decreased uptake except 
h i -  trov'ifloxacin. ~ h i c h  s h o w s  increased uptake <it 
1°C ( C / E  ratio o f 6 2  at 4°C versus 1 1  at 37°C). and 
spxfloxaciii, which is taken up by ~ieutrophils to '1 
similar extent at  4°C: and 37°C: [10-13,15-18]. Upt,ike 
of oflosacin and ciproflosacin is not affected by external 
pH, whereas uptake of trovaflosacin and pefloxacin is 
incrcased, a id  that of  sparfloxxin is decreased at  pH 8 
11 (i. 13,15,10,18]. Metabolic inhibitors d o  not seen1 
to modify drug uptake: only the high concentration 
of 3 mM N a C N  inipairs oflosacin. levoflosx-in a i d  
ciproflosaciii uptake 11 01. Various competitive inhibitors 
(e.3. hexose, nucleosides and amino acids of known 
mcmbranc transfer systems) do not impciir fluoi-o- 
cpirioloiie upt'ike. Inhibition of oflosacin uptake by 
amino acids was  previously reported by I-'ascual et al, 
hut other authors did not confirm the results of this 
All of thew studies reinforce the hypothesis tli'it 
p.is\ive di ffii s i o n  niechCi 17isms J re involved in  flu OIK- 
cl~iinolone upt'ike ~ l i d  th'it the physicoclieniical 
propci-tie\ of these drugs (e.g. ionization, lipophilicity) 
iiiriy cxpl<iiii the difference\ observed 111 cellulx 
accuiiiiil,itiori. I t  has been suggested that the efflux 
mechanism of fluoroquinolones depends on pro- 
benecid (gemfihrozi1)-inhibitable organic a n i o n  trans- 
port. To date. only norfloracin, teniaflosacin xid 
ciprofloxac.in h ~ v e  been xmssed i i i  this contest [ I  9.201. 
The m,iin con\cqnencr of  the intracellular 
. iccui i iul~~t i~~i i  of fliioi-oquinolones concerns their 
iiitr~icellulx activity. Mmy p'ithogen\ which reside i n  
phagoly sosoiiics (c. g. S t ~ i p l i ) ' / O i . i J C f L I S  n f i reus, P ~ C I  r dor r I 011115 
~ ; C ~ J I ~ ~ I I O ~ ~ ~ ,  E:ntcrobacteriaceae) are susceptible to the 
bxtericidal action of fluoroquinolones in vitro 
(Figure I ) .  I t  \eems that the intrinsic bxtericidal 
iiiechanisiii of  phagocytes (p'irticul'irly o s i d a n t  pro- 
diiction) is iiccrss'ir): for optinial activity [21]. FOI- 
intr,icellul~ir pathogens loc,ited in phagoronies (e.g. 
Lqioriclln ~"zcrrr~i[l-pliil'i, M p i b n c t e r i n ) ,  niany reports 
show th'it fluoroquinolones are also eifectivc [21,23].  
The cellular accumulation of peflosacin was  enhanced 
i n  Li:clioric,lln-infected niouse peritoneal macrophages 
compared to noii-infected cells, whereas its efflux was 
study 11 0.13,171. 
decreased, and the drug was located in the same 
conipartnient as the bacteria [ I  81. However, the 
niechaiiisms still remain unkno~vn.  
I n  vivo. in cxpcririierital models arid Various 
infectious diseases. fluoi-oquinolones have proved effec- 
tive against infections caused by intracellular pathogens. 
Since they are frequently used in iinmunocomproniised 
individuals or as combination therapy for mixed 
infections, it is interesting to note that their cellular 
uptake (at least in vitro) i \  not  niodified by vxions 
antimicrobial agents and cheiiiotlierapeutic drugs 
[9,24.25]. Targeted delivery of  fluoroquinolones b y  
drug-loaded phagocytes (e.g. polyiiiorphonuclear 
neutrophils (I'MNs)) has been suggested but no data 
are available. Modification of cell functions, px t i -  
cularly cytokine production and lymphocyte activation. 
has been observed in vitro. usudly with high, noii- 
therapeutic concentrdtion\ of  these drugs. Further 
studies are required to obtain the data. 
PHARMACOKINETICS IN HUMANS 
The 'ihsolute bio'ivdability of  selected fluoroquino- 
lorics is s h o ~ v n  in Table 2 1201. Ofloxacin. levoflosacin. 
peflosacin, fleroxacin, teiiiafloxcicin and loiiieflosacin 
are almost completely absorbed, while ciprofloxacin 
m d  enoxacin have a lo\ver bioavailabili?. The absorp- 
tion of .Yi-niethylated conipounds. such .is oflosacin, 
levoflosacin. peflos~cin cirid flerouacin. tend\ to  be 
greater than that of non-.\~~-rnrthylatt.d conipunds .  
At the acidic pH ot' the \tom,ich. ~ l l  fluoroqtiiiiolones 
<ire protoii,itrd and exist JC the c-,itionic species. 
Although the solubility of most fluoroquinolones is still 
not high at  the slightly alkLiliiie pH of the  jejunum, they 
'ire \veil absorbed i n  thc duodcnuni 'ind jejLnnum, 
possibly because the percentage oi the more lipophilic 
iieutr.il species of the agent increases. The critical role 
of  dissolved drug suggests t h t  the absorption kinetic\ 
of  fluoroqui~ioloiie~ ma): be dfrc-ted to '1 grex degree 
by their solubility ,1nd di~solution 1-ates. This i c  
supported by evidence th'it the T,,,,,, of trni~iflosacin 
formulations iiicre'iscs with dose 1261. After ordl 
'idministration. both the niaximum seriiiii concentra- 
tion (C,,,.,,) and time to  reach thic concentratiori ( . I ; , , ' ) , )  
are afiected primarily b y  the abmrption constant. 
Little is known ahout the niechnnisiii of ~ b s o r p -  
tion. Lipophilicity ceeiii\ to govern the time c o ~ i n e  
of ,ihcorptioii and is f~inction of the absorption 
coefiicicrit k, , .  Absorption of cipi-oflosacin, pefloxacin 
m d  probably other fluoroquinolones is not affected by 
age, presence of  cystic fibrosis, or rend  dysfmction 
[ 2 6 ] .  Studies in human volunteers suggest that 
absorption is passive. The fluoroquiriolones most prone 
to the effects of food 0 1 1  absorption are ciprofloxacin 
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Table 2 Phartiiacohnetic parameters 
F (96) 
Ciprofloxacin 
1)ifloxacin 
€nosacin 
Fleroxacin 
Levoflosac1n 
Lonieflosacin 
Norflosacin 
Oflosacin 
Pefloxacin 
Sparflosacin 
Temafloxacin 
Tosufloxacin 
60-70 
N A  
7(&90 
95-100 
100 
9.5-100 
<35' 
95-100 
95-100 
60' 
- 95 
<30" 
CI, (mL/min) 
550-750 
41 3b 
500-650 
100-120 
140-200 
200-250 
NA 
200-250 
100-13l~ 
160-2001' 
100-250 
NA 
C1, (mL/niin) Cl,, (niL/min) 
300-400 
4 3  
260-350 
7 ( H O  
100-1 40 
- 180 
-250 
160-200 
7-12 
15-20 
120-1 60 
90-120 
280-320 
37 0 
220-300 
25-40 
4(MO 
7 0 
NA 
40-50 
100-120 
130-170 
6(WO 
N A  
V ~ i i  (L/kg) 
25-35 
97.5' 
2.5-3.0 
0.8-1 .2<' 
1.1-1.3 
1.5-2. I' 
NA 
1.2-1.4 
1.1-1.7 
1.6-1.Q' 
1.7-2.1 
NA 
f,, ("h of dose") f'ke\ ("9 of dosr") 
5 65 15.2 
9 6  NA 
5 60 NA 
60-75 1.5 
60-90 12-15 
-70 NA 
< 30 NA 
8G90 N A  
6- 10 60' 
33-50 NA 
60-70 NA 
5 401' NA 
Adapted with permission from the American Journal of Medicine [XI. 
F = fraction of dose absorbed, C1,= total clearance; C1, = renal clcarancc; CI,,,= non-renal clearance; Vn,! = volume of distribution; 
f,, = fraction of dose excreted unchanged in  urine: it,,,, = fraction of dose excreted unchanged in feces; NA = data not available 
" Excreted as unchanged compound. 
'' CVF. 
' Vnll/F. 
I' Vd,, (Vd at steady state). 
' Percentage may be sniallrr, sincc no intravenous dosagc can bc studicd. 
' Only data on excretion of total ''C radioactivity were used; no  discrimination was made benveen parent drug and metabolite. 
a Numbers are estimates of the niniinial dose absorbed. The actual nuniber may be subrtantially higher. 
I' Dependent on food intake (without food <30; with food 540). 
and norfloxacin [26]. The extent of absorption of 
tiorfloxacin niay also be affected, but that of 
ciprofloxacin is not [26]. Total absorption of ofloxacin 
and levofloxacin is unaltered when given with 
iiornial or fat-rich food [26]. An unchanged AUC 
for fleroxacin, ofloxacin, levofloxacin, pefloxacin and 
rufloxacin suggests that N;-methylation protects 
against the effects of food. Food does not alter the 
overall absorption but prolongs the T,,,,, slightly but 
significantly [26]. Delay in gastric emptying may cause 
the increase in T,,,,, of fluoroquinolones ingested with 
fat-rich food. 
Elevated gastric pH may enhance or delay 
absorption by affecting dissolution and may shift the 
equilibriuni between ionized (less absorbed) and non- 
ionized (better absorbed) forms. Antacids may increase 
gastric emptying time and thus reduce tlie C,,,.,, and 
delay the T,,,,,. The chelating effect of antacids on 
absorption depends on the interval between fluoro- 
quiriolone and antacid intake. Therefore, the dose of 
antacid should not be given earlier than 2 h after the 
fluoroquinolone do5e. 
Most fluoroquinolones are excreted primarily by 
the kidney but the gastrointestinal route also plays a 
significant role in the overall elimination of-these agents 
1261. Hepatic elimination plays a role only for certain 
agents such as pefloxacin [26]. The physicochemical 
properties of fluoroquinolones are greatly influenced by 
their two functional groups, the carboxyl group and 
basic group, which affect pH-dependent lipophilicity. 
Many important properties of distribution may be 
explained by interactions between the pH of these 
groups and the local pH in the body. These physico- 
chemical properties may also partly explain the 
elimination properties of fluoroquinolones. They all 
undergo tubular secretion as either acids or bases and 
some are also significantly reabsorbed. Hepatic handling 
and resultant metabolite excretion is also influenced by 
K;-niethylation. 
PHARMACODVNAMICS 
Pharmacodynaniics deals with the relationship between 
exposure to a drug and a resulting effect, either 
therapeutic or toxic. Through delineation of such 
exposure-response relationships, therapy for the patient 
can be optimized and toxicity minimized while the 
therapeutic response is maximized. There have been 
many studies of anti-infective agents in which drugs of 
different classes have had their pharmacodynaniics 
determined for bacteria, as well as for other pathogens. 
For the fluoroquinolones in particular, a considerable 
amount of pharrnacodynamic data has been recorded. 
These data stem froin in vitro studies, animal models of 
infection and clinical studies. In the case of bactericidal 
agents, the rate of kill can be thought of as the 
pharniacodynaiiiic variable most closely linked to 
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organism kill at the primary infection site. To gain an 
insight into bacterial killing dynamics, two pieces of  
information are critical. T h e  first is a measure of drug 
exposure and the second is a measure of drug potency 
for the pathogen in question. 
Multiple measures of  drug exposure can be 
posited. T h e  first issue concerns whether drug con- 
centrations should be directly measured at the primary 
infection site or whether serum exposure measures will 
suffice. I n  the majority of  cases, the pharrnacokinetics 
are linear. Therefore, first-order rate constants will link 
drug transfer from serum to the site of  infection. 
Consequently, while the actual concentration-time 
profiles will differ slightly between two sites, linkage 
to  the effect will not be impeded, as different para- 
meters will be obtained for whatever function is 
employed for the analysis. Consequently, either central 
o r  peripheral compartment concentrations may be 
used. For ease of  data collection, this will usually result 
in  serum data being chosen for the pharmacodynamic 
andysis. 
Reducing the number of pathogens located at the 
yite of infection is the primary target of  an antibiotic. 
Only the drug concentration at the site of  infection 
is relevant for its degree of  efficacy. However, it is 
not possible to determine the exact location of the 
infection where the concentration of  interest should be 
meawred. In general, therefore, the seruni concentra- 
tion is used as a surrogate marker of  the infection 
compartment concentration. After administration of an 
antibiotic, the infection site concentration will follow 
the changes in serum concentration. This delay is 
characterized by an equilibration half-time. When 
pharmacokinetics are linear and a steady-state situation 
is established, the infection site concentration is directly 
proportional to  the serum concentration, which reflects 
exposure of the pathogens to the drug and, therefore, 
should be a good surrogate marker (Figure 2). 
For 5ituations where different organisms will be 
part of the analysis (as in the analysis of  clinical trial 
data), it  is important to noririalize the drug exposure t o  
the nieasui-e of  potency of the drug for the pathogen 
(in most instances, this will be the MIC).  This results 
in  three pharmacodynaniic variables which are drawn 
from various aspects of  the shape of  the concentratioii- 
time curve: the peak/MIC ratio, the AUC/MIC ratio 
(AUIC) a n d  the time>MIC, which may all be linked 
to outconie. If the peak/MIC ratio is linked to 
outconie, this indicates that relatively infrequent dosing 
intervals xvould lead to the best results, with production 
of a very peaked shape for the concentratiori-time 
curve. T h e  AUC/MIC ratio would indicate that the 
therapeutic outcome is independent of curve shape, 
a i d  tinie>MIC would mean that flat curve shapes 
0 4 8 12 16 20 24 
Time (h) 
Figure 2 Pharmacokinetic surrogate relationyhips. AU<: = 
area under thc scrum concentration time curve; C,,,,,= 
maximum serum concentration; MIC: = minimum inhibitory 
concentration: T>MIC = time that the serum concentration 
exceeds the MIC. 
which keep trough levels high would produce the best 
results. 
Fluoroquinolones not only have activiq against 
extracellular pathogens but are also active against 
intracellular pathogens such AS A4yroylarriio and 
Qzluriiydia, amongst others. Their ability to enter cells 
is probably the key to their activity against these 
pathogens. Generally, they penetrate well into most 
cellular compartments where these organisms reside. In 
addition, the uptake into cells may explain some of the 
findings of  the concentration-time curve in the lung for 
fluoroquinolones when measured by the technique 
described by Baldwin et a1 1271. Concentrations of 
fluoroquinolones in extracellular fluid often consider- 
ably exceed those seen in the serum. A partial explan- 
ation for this is efflux of  drug from lung cells and lung 
niacrophages, which concentrates fluoroquinolones 
intracellularly because of  ion-trapping effects. When 
serum co~iceiitratio~is decline, this could ‘illow efRux of 
drug from cellular reservoirs which would maintain 
drug concentrations locally in excess of  the serum levels. 
The  concentration dependence of  the bacterial kill 
rate will deteriiiine which of  these dynamic variables is 
very concentration-depeiideiit in kill rate (as is the case 
with p-lactani agents), the rate of kill cngendered by 
high concentrations around the peak will not differ 
cubstantially from the kill rate engendered by concen- 
trations doivn near the MIC.  Consequently, the 
number of organisms killed by a dose of drug will be 
relatively constant, i.e. the kill rate multiplied by the 
time that the co~iceiitratioii exceeds the MIC.  In this 
most closely linked to organism kill. If the drug ’ 1s ’ not 
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case, tinie>MIC would be the pharniacodynamic 
variable of interest. 
For drugs which are very concentration-dependent 
in kill rate (e.g. fluoroquinolones and aminoglycosides), 
the kill rate changes continuously with concentration, 
and the total number of organisms killed is provided by 
the path integral of kill rate (which is concentration- 
dependent) over time. That is, the kill rate near the 
peak multiplied by the duration over which it is 
appropriate (i.e. until the concentration is reached 
which produces a noticeably changed kill rate) plus the 
next kill rate multiplied by the time over which it is 
effective, and so on. With this situation, the AUC/MIC 
ratio should be most closely linked to outcome, as the 
AUC is, itself, the integral of the concentration-time 
curve. 
The peak/MIC ratio should never be linked to 
outcome in the scenario created. Were this so, there 
would be an identifiable dose of drug which had 
demonstrable activity, whereas half this dose would 
have markedly reduced activity to alniost nil. In 
general, antibiotics do not behave in this manner 
because the scenario, as generated, is incomplete and 
examines the sensitivity of the organism to the drug as 
a static phenomenon. However, it is known that dense 
bacterial populations, such as are seen in serious 
infections, are composed of distributions of organisms, 
some of which may be spontaneously mutated to 
altered drug susceptibility. Frequently, there will be a 
number of resistant mutants in large populations of 
organisms. In the case of nosocomial pneumonia, 
where Enterobacter cloacae and l? aeruginosa are common 
pathogens, bacterial densities are high and there is 
considerable pus in the chest, giving a total population 
of 10'"-10". Mutational frequencies for resistance 
differ, and for these pathogens, mutational frequencies 
are in the order of 10*-10' and 106-107, respectively. 
Consequently, there are 10'-10' resistant organisms 
present before any selective pressure (antibiotic admin- 
istration) has been applied. 
With fluoroquinolones, resistant Gram-negative 
organisms are frequently mutated in the gyrA gene, and 
Gram-positive bacteria in the parC gene, with single 
point mutations most frequently causing a four- to 
eight-fold shift in the MIC. The size of the MIC 
change is important, because larger changes (normally 
16- to 128-fold), as are seen with the selection of 
mutants stably derepressed for Bush class I enzyme 
production by some p-lactams, could not be counter- 
selected with a greater dosing intensity. It  may be that 
peak/MIC plays a role here. If a high enough peak/ 
MIC ratio can be achieved, not only may the parent 
organism be killed, but also the g p 4  mutant (or any 
other type of mutant with a relatively low change in 
MIC) may be suppressed. Consequently, while 
AUC/MIC can be thought of as being linked to cell 
kill for the parent strain, for peak/MIC suppression of 
resistant subpopulations should be considered as well. 
In vitro data 
Studies which have shed considerable light on fluoro- 
quinolone pharmacodynamics are those by Blaser et a1 
and Dudley et al, employing the hollow-fiber pharma- 
codynamic model [28,29]. This model is particularly 
instructive, as human serum pharmacokinetic-time 
profiles can be simulated and effects on organism load 
ascertained. Blaser et al examined enoxacin against 
a strain of Klebsiella pnecrmoniae [28]. In a series of 
experiments, once-daily dosing with enoxacin was 
compared with half the dose administered twice daily 
(same total daily dose). In one of three experiments 
with twice-daily dosing, there was clearcut break- 
through growth which was not seen with once-daily 
dosing (Figure 3) [28]. They then performed a large 
number of experiments and plotted residual organisms 
determined at the end of the experiment. As can be 
seen in Figure 4 [28], when an organism-dosing 
regimen pair had a resultant peak/MIC ratio of 10/1 
or greater, the unit was always completely sterilized. 
This is important, as it lends credence to the idea of 
suppressing resistant mutants by employment of specific 
dosing regimens. 
This idea was directly addressed by Dudley et a1 
with I? aertrginosa [29]. They simulated an intravenous 
dose of ciprofloxacin 200 mg on a 12-hourly schedule 
(a regimen then in frequent clinical use). The baseline 
bacterial population was examined on agar plates 
containing differing concentrations of ciprofloxacin. 
This was then repeated prior to the 12-h simulated dose 
and again at 24 h. The administration of ciprofloxacin 
at a suboptimal dose rapidly selected the resistant part 
of the initial bacterial population (Figure 5) [29]. As 
well as amplifying the resistant mutant subpopulation, 
this model enables the effects of altering dose and 
schedule on bacterial cell kill to be seen. It  also 
provided the first clue that dosing could be modified to 
obtain a specific end: suppression of the resistant part 
of the bacterial population. 
Animal models 
Leggett et a1 and Fantin et a1 provided considerable 
insight into the pharmacodynamics of fluoroquino- 
lones in an animal infection model [30,31]. This was 
the standardized neutropenic mouse thigh infection 
model employed by Craig's laboratory in which nlice 
are made neutropenic with cyclophosphamide [32].  
The pathogen is injected into the mouse thigh and 
allowed to multiply for several hours. Antimicrobial 
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regimens are then initiated and the mice sacrificed at 
various time points, and the number of organisnis in 
the thigh determined. Large numbers of doses and 
schedules are examined and the linkage of one of the 
three above mentioned pharniacodynaniic variables 
determined by multivariate regression analysis. For 
fluoroquinolones, it was clear that the AUC/MIC ratio 
was the dynamic variable most clearly linked to 
outcome. This supports the theory that drugs which are 
concentration-dependent in kill rate will have an 
AUC/MIC ratio linked to outcome. However, it seems 
to contradict the data of Blaser et a1 and Dudley et a1 
128,291. 
Some insight into this discrepancy was provided 
by Drusano et a1 employing a neutropenic rat model 
first described by Johnson [33,34]. R a t s  are made 
profoundly neutropenic with cyclophosphamide and 
then challenged with a dense inoculuni intraperitone- 
ally. As in the Craig model, the organisms are allowed 
to multiply before therapy is initiated. However, in this 
model, there is very reliable bactereniia and survival is 
used as the endpoint. An important point to emphasize 
is that the inoculum in the Craig model is of the order 
of 10" nlicroorganisms, while in the Johnson niodel (at 
least in this series of experiments) an inoculum of 10" 
I? aevugirzosn bacteria (1 00 x LDjo) was employed. As 
might be expected, there is a relatively low probability 
that a resistant mutant will be included in the inoculuni 
in the Craig model, whereas the larger inoculuni in the 
Johnson model provides a much higher probability of 
having multiple resistant mutants in the population 
(mutational frequency for fluoroquinolone resistance 
in Pseudomonas spp. is frequently in the range of 
1 0"-I 0 7 ) .  
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A series of dose-finding experiments identified 
80 nig/kg of lomefloxacin as the dose which would 
generate approximately 70% survival in this model [33]. 
This is still on the relatively steep part of the exposure- 
response curve. An experiment was then performed 
with 200 animals (50 animals per group). One group 
received saline placebo, while the other three all 
received 80 rng/kg per day, but on three different 
schedules of administration (80 nig/kg o.d., 40 mg/kg 
b i d .  and 20 nig/kg q.i.d.). A pharniacokinetic study 
documented that the AUCs were not statistically 
different for the three regimens and, thus, all had the 
same AUC/MIC ratio. As expected, the 0.d. dosing 
group had the highest peak/MIC ratio, while the 
20 mg/kg four times a day group had the longest 
tinie>MIC. If A U U M I C  were linked to outcome, all 
three regimens should provide the same outcome. If 
tinie>MIC were linked to outcome, four times a day 
dosing should be best, and if peak/MIC ratio is the 
linked dynamic variable, o.d. dosing should provide the 
greatest survival. The results are shown in Figure 6 [33].  
Two things are evident. The first is that o.d. dosing 
provided a significantly better outcome (y<0.001). 
The second is that the survival curves for the other 
groups are, in essence, identical. This caused us to 
hypothesize that, when peak/MIC ratio does not 
exceed 1 O : l  (as it did not in the 40 mg/kg twice a day 
and 20 rng/kg four times a day groups), the dynaniic- 
ally linked variable is the AUC/MIC ratio. When this 
ratio is achieved, the peak/MIC ratio explains outcome 
better, most likely for the reasons evident in the Blaser 
et a1 and Dudley et a1 in vitro experiments, i.e. suppres- 
sion of emergence of resistance [28,29]. The second 
experiment examined three dosing groups of 20 
animals each (control, 40 nig/kg o.d. and 20 mg/kg 
twice a day). The results are shown in Figure 7 [33].  
Clearly, when none of the regimens could produce a 
peak/MIC ratio of >10:1, AUC/MIC was seen to 
be linked to outcome (no difference between o.d. and 
twice a day dosing). 
The experiments above examined the issue of 
response with changing drug exposure, with the MIC 
constant. The third set of experiments addressed 
holding the exposure constant and examining outcome 
as a function of changing MIC. T~vo mutant organisms 
were selected and found to have stable MICs of four 
2nd eight times that of the parent strain (MICs of 1 ,  4 
and 8 mg/L). Consequently, challenges were used with 
the same genetic background and virulence, but 
differing in MIC. Four dosing groups (plus three 
control groups not displayed) were examined. A 
reginien of 80 nig/kg o.d. was used for each of the 
three organisms with the different MICs, producing 
both peak/MIC and AUC/MIC ratios for the three 
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Figure 7 Dose fractionation experiment 2. The MIC of lomefloxacin for the challenge organism was 1 mg/L. There were 
20 animals evaluated per group [33]. Reproduced with permission from Antimicrobial Agents and Chemotherapy. 
groups in ratios of 8:4:1. The fourth group employed 
2 dose of 20 mg/kg with the MIC= 1 mg/L challenge 
organism, producing peak/MIC and AUC:/MIC ratios 
equivalent to the group with 80 mg/kg 0.d. dosing and 
J MIC=4 mg/L challenge organism. The results are 
shown in Figure 8 [33]. 
Changing organism MIC had, as expected, a pro- 
found effect on the outcome seen. Most importantly, 
outcomes were essentially identical for the two groups 
with identical AUC/MIC and peak/MIC: ratios. This 
indicates that it does not matter whether the MIC (a 
more or less sensitive organism is being treated) or the 
exposure (larger or smaller doses are employed for 
treatment) are changed; the outcome is driven by the 
ratio of exposure to MIC (peak/MIC or AUC/MIC), 
however it is achieved. 
Clinical studies 
The first clinical data regarding the pharmacodynamics 
of fluoroquinolones were published by Peloquin et a1 
[35]. They examined ciprofloxacin in a study ofpatients 
with lower respiratory tract infection caused by Gram- 
negative bacilli and concluded that time>MIC was 
the pharniacodynamic variable most closely linked to 
outcome. This somewhat discordant result was modified 
by their finding that the emergence of resistance among 
I? aevuginosa was, indeed, driven by having a peak/MIC 
ratio which did not exceed 10:l. 
Further patients were studied and the data re- 
analyzed by Forrest et al [36,37]. Patients were classified 
as having succeeded or failed clinically and niicro- 
biologically but, importantly, the lower respiratory 
tract flora were sampled daily and the time to initial 
pathogen eradication determined. The first two end- 
points were subjected to logistic regression analysis, and 
the time to eradication endpoint was examined by Cox 
proportional hazards modeling. 
The logistic regression analysis produced statistic- 
ally significant linkages between the AUC/MIC ratio 
and both the probability of clinical success and that of 
microbiological success. It should be noted, however, 
that the authors also indicated that the correlation 
between AUC/MIC ratio and peak/MIC ratio in their 
population was 0.9. The Cox proportional hazards 
modeling again showed a significant linkage between 
AUC/MIC ratio and the time to bacterial eradication. 
Indeed, they also showed differences by AUC/MIC 
thresholds. A patient with an AUC/MIC ratio 9125 
had significantly shorter times to eradication than a 
patient with a smaller AUC/MIC ratio. Further, a 
patient with an AUC/MIC ratio 2250 had a time to 
eradication significantly shorter than a patient with a 
ratio between 125 and 249 (Figure 9) [37]. These data 
are an elegant validation of the in vitro and animal 
model data. However, it should be recognized that the 
analysis was retrospective. Further, it should be empha- 
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sized that the outcome is specific to the population 
from which the patients were drawn: mainly elderly 
patients with very severe hospital-acquired lower 
respiratory tract infection (the majority due to Gram- 
negative pathogens) on mechanical ventilation. The 
findings should not be extrapolated beyond this group. 
Most recently, Preston et a1 reported the first 
prospective, multicenter trial for the explicit purpose of 
determining the pharmacodynamics of an anti- 
microbial agent [38,39]. Levofloxacin 500 mg 0.d. was 
employed for the treatment of community-acquired 
lower respiratory tract infections, complicated and 
uncomplicated skin and soft tissue infections and 
uncomplicated urinary tract infections. An optimal 
sampling analysis was performed to guide clinical 
investigators in the acquisition of serum samples for 
later analysis. This sample design was employed at all 
22 centers, and 1524 serum samples were obtained 
from 274 patients (of 313 entered into the study). 
These were analyzed for levofloxacin, and the resultant 
concentrations were subjected to a population pharma- 
cokinetic analysis. The population means and the 
Associated co-variance matrix were used to estimate the 
pharmacokinetic parameter values for each patient 
through the use of maximum a posteriori probability 
(MAP) Bayesian estimation. 
A total of 134 patients had a microbiologically 
documented infection with an MIC determined for 
levofloxacin. Logistic regression analysis was performed 
for clinical and microbiological outcome, employing 
pharmacodynamic co-variates as well as other demo- 
graphic and clinical co-variates. The result was clearcut, 
with the peak/MIC ratio being significantly linked to 
both clinical and microbiological outcome. As in the 
Forrest study, there was a high degree of correlation 
between peak/MIC and AUC/MIC, with a correlation 
coefficient value exceeding 0.9. Further, a classification 
and regression tree analysis was performed to see if a 
breakpoint could be ascertained. It was found that a 
peak/MIC ratio of > 12 was associated with both the 
best clinical and the best microbiological outcomes (it 
should also be recognized that the response rate below 
the ratio of 12 still exceeded 80%). This finding agrees 
remarkably well with the data of Blaser et al where a 
peak/MIC ratio of 10 was identified as producing 
optimal bacteriologic outcomes [28]. The same caveats 
apply to this study as to that of Forrest et a1 [36,37]. 
This was a study of community-acquired infections 
in moderately ill patients. Its results should not be 
extrapolated beyond the population studied. 
How then, can these two studies be reconciled? 
The answer comes from the in vitro and animal model 
studies. An analysis will find AUC/MIC linked to 
outcome if, on average, the peak/MIC ratio is < lo .  
Otherwise, peak/MIC will appear to be linked to 
outcome, probably because of suppression of emerg- 
ence of resistant mutants. In the Forrest study, it is clear 
that approximately 50% of the patients developed 
peak/MIC ratios of <10 [36,37]. This is because of the 
large mixture of patients in this study with Staphy- 
lococcus atireus, I! aeruginosa and Enterobacter cloacae, all 
pathogens with higher MICs for fluoroquinolones, 
including ciprofloxacin. In the studies by Preston et al, 
80% of patients developed peak/MIC ratios of B 10, 
almost certainly because of the common pathogens 
encountered in the community [38,39]. Consequently, 
it is not surprising that the studies of Forrest et a1 
identified AUC/MIC ratio as the primary pharmaco- 
dynamically linked variable for fluoroquinolones, while 
the studies of Preston et a1 identified peak/MIC ratio 
as the dynamically linked variable [36-391. 
It should be noted that the guidance for the 
interpretation of the clinical data came from the in vitro 
and animal model systems. In part this is because of the 
clinical reality since it is almost unheard of for different 
schedules of administration to be tested in clinical trials 
with adequate numbers of patients. Consequently, in 
large trials, a drug is administered on a fixed dose and 
schedule and thus there is a large degree of co-variance 
between pharniacodynamic variables. In this situation, 
the peak/MIC ratio cannot be increased without 
also increasing the AUC/MIC ratio and time>MIC. 
Therefore, it should not be surprising that different 
trials can find different dynamically linked variables, 
depending on the populations and pathogens studied. 
These differences, it should be noted, are readily 
explained by the lessons learned from the in vitro and 
animal model systems. 
CONCLUSIONS 
The pharniacodynamic effect of fluoroquinolones can 
only be understood in a rational manner if the 
information regarding them is integrated from at least 
four sources. Obviously, some measure of potency of 
the drug for the organisms in question is a critical piece 
of information, and most clinicians obtain this from a 
knowledge of the drug’s MIC for clinically important 
pathogens. More than for most anti-infectives, the 
pharmacokinetic profile of the fluoroquinolones also 
plays a major role in determining the observed pharma- 
codynamics. As has been demonstrated in an animal 
model of neutropenic infection, it is actually the ratio 
of these two things (some measure of drug exposure, 
either peak concentration or AUC, and organism 
MIC) which mostly determines the observed pharma- 
codynamic effect [33]. 
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However, it should be realized that the differences 
in pharmacokinetic profile among the fluoroquino- 
lones are close to the differences in their niicrobio- 
logical activities. For most of the fluoroquinolones, 
protein binding is low and almost negligible (-30%). 
However, for some newer drugs, the binding is 
somewhat greater (-70%) and may adversely impact 
upon their microbiological activity. This needs to be 
taken into account in any comparative analysis. Finally, 
the ability of these drugs to penetrate cells adds many 
intracellular pathogens to their spectrum of activity. 
Insight into the physicochemical properties ofthe drugs 
which promote this cellular penetration is key for 
coiiiparing these agents. 
Fluoroquinolones are the first new class of antibac- 
terials for which a detailed pharniacodynaniic under- 
standing of their action has been gained early in the 
course of development. This understanding comes from 
in vitro data, animal models of infection and, uniquely, 
clinical trial data. This knowledge has led to the 
optimization of dose schedule for the newer drugs (e.g. 
demonstrating once-daily dosing is supportable), the 
ability to compare different drugs within the class on a 
rational basis and, perhaps most importantly, the ability 
to optimize the clinical and microbiological outcome for 
seriously ill patients on the bask of organism MIC and 
observed or expected serum drug concentrations. 
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